We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+14.15%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$736M
AUM Growth
+$94.9M
Cap. Flow
+$68.2M
Cap. Flow %
9.27%
Top 10 Hldgs %
43.9%
Holding
93
New
21
Increased
19
Reduced
26
Closed
17

Top Buys

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$30.8M
2
CRL icon
Charles River Laboratories
CRL
+$27.9M
3
LLY icon
Eli Lilly
LLY
+$25.6M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$20.8M
5
NVST icon
Envista
NVST
+$18.2M

Top Sells

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$14.8M
2
ANAB icon
AnaptysBio
ANAB
+$13.6M
3
UTHR icon
United Therapeutics
UTHR
+$13.6M
4
ANGO icon
AngioDynamics
ANGO
+$13M
5
APEN
Apollo Endosurgery, Inc.
APEN
+$11.8M

Sector Composition

Rank Sector Weight
1 Healthcare 92.93%
2 Consumer Staples 4.27%
3 Financials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$26.3B
$49.2M 6.68%
234,859
-60,682
-21% -$13.6M
ISEE
2
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$44.9M 6.1%
2,502,601
+1,588,255
+174% +$20.8M
FOCL
3
EDAP TMS S.A.
FOCL
$231M
$40.3M 5.48%
4,889,745
+1,605,556
+49% +$12.2M
SKIN icon
4
SkinHealth Systems
SKIN
$98.3M
$31.4M 4.27%
2,665,876
-610,161
-19% -$7.71M
ILMN icon
5
Illumina
ILMN
$28.7B
$28.9M 3.93%
+155,845
New +$30.8M
CVS icon
6
CVS Health
CVS
$137B
$27.3M 3.7%
285,900
+66,500
+30% +$6.58M
BCAB icon
7
BioAtla
BCAB
$5.63M
$26.2M 3.56%
68,010
+2,756
+4% +$902K
LLY icon
8
Eli Lilly
LLY
$1.07T
$26.1M 3.55%
+80,800
New +$25.6M
CRL icon
9
Charles River Laboratories
CRL
$10.8B
$25.4M 3.45%
+129,100
New +$27.9M
SRDX
10
DELISTED
Surmodics
SRDX
$23.4M 3.17%
768,478
+107,474
+16% +$3.69M
ACLX
11
DELISTED
Arcellx
ACLX
$23.3M 3.16%
1,239,913
+330,174
+36% +$6.32M
ORGO icon
12
Organogenesis Holdings
ORGO
$328M
$21M 2.86%
6,489,063
+1,202,896
+23% +$5.44M
IRMD icon
13
iRadimed
IRMD
$1.21B
$20.6M 2.8%
684,690
+63,925
+10% +$2.23M
TNDM icon
14
Tandem Diabetes Care
TNDM
$1.18B
$19.9M 2.7%
415,200
+231,400
+126% +$12.7M
THER
15
DELISTED
THERATECHNOLOGIES INC COM
THER
$19M 2.58%
8,007,714
+185,302
+2% +$439K
NVST icon
16
Envista
NVST
$4.34B
$15.7M 2.14%
+480,000
New +$18.2M
KRYS icon
17
Krystal Biotech
KRYS
$10.4B
$14.5M 1.96%
207,332
-7,150
-3% -$517K
CCCC icon
18
C4 Therapeutics
CCCC
$397M
$12.6M 1.72%
1,441,513
+1,158,873
+410% +$12M
AMLX icon
19
Amylyx Pharmaceuticals
AMLX
$2.16B
$12.1M 1.64%
+429,336
New +$10.7M
NTRA icon
20
Natera
NTRA
$37B
$12.1M 1.64%
275,673
+143,800
+109% +$6.85M
INSP icon
21
Inspire Medical Systems
INSP
$1.47B
$12M 1.62%
67,400
-21,550
-24% -$4.33M
CUTR
22
DELISTED
Cutera, Inc.
CUTR
$11.7M 1.58%
255,792
-1,808
-0.7% -$82.5K
DICE
23
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$10.9M 1.48%
535,358
-280,382
-34% -$5.11M
CVRX icon
24
CVRx
CVRX
$129M
$9.88M 1.34%
1,059,040
– –
IOVA icon
25
Iovance Biotherapeutics
IOVA
$2.19B
$9.82M 1.33%
1,025,200
+305,600
+42% +$3.52M
1
2 3 4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
JC
JB Capital Wethersfield, Connecticut $2.48B AUM 22.31% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BW
BIP Wealth Atlanta, Georgia $2.46B AUM 14.38% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return

Soleus Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Soleus Capital Management held 93 positions worth $736M, up 15% from $641M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Soleus Capital Management deployed $68.2M of net new capital in Q3 2022, opening 21 new positions and adding to 19 existing holdings. Its largest new stake was Illumina: 155,845 shares worth $28.9M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 87% a quarter earlier, followed by Consumer Staples and Financials.

On the sell side, the largest reduction was Viridian Therapeutics, an estimated $14.8M trimmed.

  • Soleus Capital Management's largest Q3 2022 buy was Illumina: 155,845 shares worth $28.9M.
  • Soleus Capital Management added most to IVERIC bio, Inc. Common Stock in Q3 2022, an estimated $20.8M increase.
  • Soleus Capital Management's biggest Q3 2022 reduction was Viridian Therapeutics, cutting an estimated $14.8M.
  • Soleus Capital Management fully exited AngioDynamics in Q3 2022, selling an estimated $13M.
  • Soleus Capital Management's ten largest holdings make up 44% of its $736M portfolio in Q3 2022.
  • Soleus Capital Management opened 21 new positions and closed 17 in Q3 2022.
  • Soleus Capital Management's portfolio value rose 15% quarter-over-quarter to $736M.

Based on Soleus Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.